Operating cash flow was negative in nine of ten quarters and free cash flow was negative throughout with zero CapEx, implying sustained cash burn that investors should monitor against the $3.0M cash balance and the $3.2M net acquisition outflow in 2026Q2.
Eocene Ltd. (EOCN) cash flow statement — 14-year operating, investing & financing cash flows
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 | Dec'12 |
|---|
| Cash from Operations | -8.54M | -6.32M | -5.88M | -6.14M | -18.5M | -32.89M | -26.29M | -14.94M | -9.02M | -12.07M | -12.13M | -8.47M | -9.24M | -2.52M | -3.08M |
| Operating CF Margin % | - | - | - | - | - | - | - | - | -442.74% | -1112.17% | -2597.22% | - | - | - | - |
| Operating CF Growth % | -265.7% | -7.4% | 4.19% | 66.83% | 43.75% | -25.13% | -75.99% | -65.54% | 25.23% | 0.51% | -43.13% | 8.3% | -266.13% | 18.03% | - |
| Net Income | -11.34M | -10.31M | -7.52M | -6.91M | -17.87M | -32.47M | -28.77M | -20.46M | -9.86M | -12.3M | -16.95M | -10.62M | -9.1M | -17.48M | -3.15M |
| Depreciation & Amortization | 0 | 0 | 83K | 31K | 35K | 42K | 39K | 35K | 387K | 239K | 169K | 50K | 9K | 4K | 5K |
| Stock-Based Compensation | 501K | 546K | 531K | 892K | 1.3M | 1.89M | 2.07M | 2.23M | 1.78M | 1.39M | 1.63M | 970K | 601K | 10.85M | 208K |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 84K | -437K | -114K | 12K | 164K | -1.4M | -920K | -601K | 0 | -208K |
| Other Non-Cash Items | 2.54M | 2.54M | 1.75M | -280K | 485K | 13K | -285K | -63K | -144K | -167K | 1.67M | 1.06M | 601K | 2.89M | 208K |
| Working Capital Changes | -238K | 912K | -728K | 132K | -2.45M | -2.45M | 1.1M | 3.44M | -1.21M | -1.4M | 2.75M | 986K | -748K | 1.22M | -143K |
| Change in Receivables | 108K | 240K | -192K | 345K | 300K | -313K | 15K | -609K | -63K | 129K | 95K | -214K | -149K | -2K | -11K |
| Change in Inventory | 0 | 0 | 0 | 0 | -300K | 313K | -15K | 609K | -142K | 671K | 81K | 39K | -91K | 228K | -103K |
| Change in Payables | 520K | 695K | -571K | -681K | -2.31M | -2.17M | 1.05M | 4.18M | -462K | -846K | 863K | 1.38M | -480K | 954K | -89K |
| Cash from Investing | 3.82M | -3.38M | -1.11M | 800K | 17.56M | 11.46M | 16.54M | 6.68M | -60.02M | 6.44M | 6.34M | -11.11M | -9.02M | 3K | -32K |
| Capital Expenditures | 0 | 0 | 0 | 0 | -4K | -11K | -44K | -12K | -90K | -21K | -17K | -159K | -770K | -13K | -32K |
| CapEx % of Revenue | - | - | - | - | - | - | - | - | 4.42% | 1.94% | 3.64% | - | - | - | - |
| Acquisitions | -3.18M | 0 | 0 | -1.5M | -17.57K | 0 | -24.94M | 21.8M | 6.08M | 0 | 13K | -6M | 8.25M | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | -250K | 0 | 17.57K | -1K | 24.94M | -21.8M | -6.08M | 9K | 13K | 6M | -6M | 16K | 0 |
| Cash from Financing | 2.68M | 9.03M | 8.79M | 6.18M | 70K | 17.37M | 768K | 143K | 80.18M | 15.55M | 4.73M | 0 | 41.86M | 1.94M | 3.68M |
| Debt Issued (Net) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1.82M | 20K |
| Equity Issued (Net) | 2.68M | 9.03M | 8.79M | 6.18M | 70K | 17.37M | 707K | 0 | 79.15M | 15.02M | 4.48M | 0 | 41.86M | 120K | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 0 | 0 | 0 | 0 | 0 | 0 | 61K | 143K | 1.03M | 530K | 255K | 0 | 0 | 0 | 3.66M |
| Net Change in Cash | -2.04M | -664K | 1.79M | 848K | -868K | -4.06M | -8.98M | -8.12M | 11.14M | 9.92M | -1.06M | -19.58M | 23.6M | -581K | 572K |
| Free Cash Flow | -8.54M | -6.32M | -5.88M | -6.14M | -18.5M | -32.9M | -26.33M | -14.95M | -9.11M | -12.09M | -12.15M | -8.63M | -10.01M | -2.54M | -3.11M |
| FCF Margin % | - | - | - | - | - | - | - | - | -447.15% | -1114.1% | -2600.86% | - | - | - | - |
| FCF Growth % | -56.24% | -7.4% | 4.19% | 66.84% | 43.76% | -24.96% | -76.14% | -64.04% | 24.61% | 0.48% | -40.69% | 13.76% | -294.6% | 18.45% | - |
| FCF per Share | -8.97 | -11.72 | -50.54 | -212.73 | -88.32 | -160.52 | -148.48 | -84.96 | -60.29 | -116.16 | -128.14 | -11.67 | -14.55 | -3.56 | -9.21 |
| FCF Conversion (FCF/Net Income) | 0.75x | 0.61x | 0.78x | 0.89x | 1.04x | 1.01x | 0.91x | 0.73x | 0.92x | 0.98x | 0.72x | 0.80x | 1.02x | 0.14x | 0.98x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 865K | 0 | 382K | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 75K | 0 | 106K | 0 | 1K | 0 | 0 |
Quick answers to the most common questions about buying EOCN stock.
Eocene Ltd. (EOCN) generated $-6.3M in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.
Eocene Ltd. (EOCN) reported negative free cash flow of $6.3M in 2025, indicating capital requirements exceeded cash from operations.
Eocene Ltd. (EOCN) spent $0.0M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.
Key Metrics
Top Statement Risk
Sustained operating cash burn
Losses Paired With Persistent Cash Burn
Based on EOCN's reported quarterly figures, operating cash flow was negative in nine of the ten quarters from 2024Q1 through 2026Q2, with the OCF-to-net-income ratio ranging widely from 0.40 to 1.44 and offering little evidence of earnings quality beyond the losses themselves.
Because net income is negative in every period, the OCF/NI ratios are mechanically positive but do not indicate healthy conversion; they simply reflect both measures being negative. The more meaningful observation is that operating cash outflows are of similar magnitude to reported losses, suggesting that non-cash charges such as stock-based compensation, which is modest at roughly $100K to $240K per quarter, explain only a small share of the gap. Investors should monitor whether the cash burn tracks R&D spending, which the prior income statement analysis identified as the dominant cost line.
Free Cash Flow Negative Without Revenue Base
As reported in EOCN's quarterly cash flow data, free cash flow was negative across all ten quarters, with no revenue recorded to compute a free cash flow margin and CapEx remaining at zero throughout the period.
The absence of any revenue denominator means FCF margin analysis is unavailable, and the cash flow profile reflects a pre-commercial operating structure rather than a business generating cash at scale. Reported free cash flow of roughly -$1.0M to -$2.5M per quarter is consistent with an entity funding development activity from its existing resources. This trajectory suggests the company's cash requirements are driven by operating spending rather than investment in productive assets.
Zero Capital Spending Signals Asset-Light Model
According to reported figures, EOCN recorded zero capital expenditure across all ten quarters, and with no depreciation and amortization of note beyond minor amounts, the company does not appear to be building a physical asset base.
The absence of CapEx is consistent with a development-stage biotech profile in which spending is concentrated in research rather than facilities or equipment. This reduces the risk of unrecovered fixed-asset investment but also means the company has not yet built capacity that would support future commercialization. Investors should note that the cash requirement sits entirely in operating expenses rather than capital investment.
No Shareholder Returns Amid Acquisition Activity
Based on EOCN's reported figures, dividends and share buybacks were zero across the period, while a single reported net acquisition outflow of roughly $3.2M in 2026Q2 stands out against otherwise minimal investing activity.
The absence of dividends and repurchases is expected for a loss-making company whose cash is being consumed by operations, so capital is effectively not being returned to shareholders. The 2026Q2 acquisition outflow is the single investing event of note and warrants further investigation into its purpose and strategic rationale, since it is large relative to the company's quarterly operating burn. Without disclosure of the acquired asset, its contribution to future cash generation cannot be assessed from the supplied data.
Cumulative Losses Raise Funding Questions
Based on reported quarterly figures, cumulative net losses across the ten periods exceed $20M while operating cash outflows have been sustained, raising questions about how long current resources can support operations without additional financing.
The reported cash flow data does not disclose the company's cash balance or financing arrangements, so runway cannot be quantified directly from the supplied information. The pattern of recurring operating outflows, combined with the acquisition outflow in the most recent quarter, suggests the balance sheet may be under increasing pressure, though this remains an inference that should be verified against the full balance sheet. Investors should monitor future equity issuance or dilution, which the earnings-per-share volatility noted in the income statement analysis may already partly reflect.